Iniparib

Iniparib is a drug that was initially believed to be a PARP inhibitor, which are a group of pharmacological inhibitors of the enzyme called Poly (ADP-ribose) polymerase. It was developed by Sanofi-Aventis for the treatment of various types of cancer, including breast cancer and lung cancer. However, later studies suggested that Iniparib does not work by inhibiting PARP.

History

Iniparib was first developed by Sanofi-Aventis, a global pharmaceutical company. It was initially classified as a PARP inhibitor, a type of drug that prevents the repair of DNA damage in cancer cells, thereby leading to their death. Early clinical trials showed promise, particularly in the treatment of triple-negative breast cancer, a subtype of breast cancer that is particularly difficult to treat.

However, later studies, including a Phase III clinical trial, failed to confirm these initial positive results. Furthermore, subsequent research suggested that Iniparib does not function as a PARP inhibitor. The exact mechanism of action of Iniparib remains unclear.

Mechanism of Action

The exact mechanism of action of Iniparib is not fully understood. It was initially believed to function as a PARP inhibitor, preventing the repair of DNA damage in cancer cells and thereby leading to their death. However, later research suggested that it does not inhibit PARP.

Despite this, Iniparib has been shown to have anti-cancer effects. It is thought to work by forming toxic adducts with proteins and DNA in cancer cells, leading to their death. However, more research is needed to fully understand how Iniparib works.

Clinical Trials

Iniparib has undergone several clinical trials for various types of cancer. Early trials showed promise, particularly for the treatment of triple-negative breast cancer. However, a Phase III clinical trial failed to confirm these initial positive results.

Despite these setbacks, Iniparib continues to be studied for potential use in treating other types of cancer, including lung cancer and ovarian cancer.

See Also

• PARP inhibitor
• Sanofi-Aventis
• Breast cancer
• Lung cancer